Epigenetic mechanism involved in the HBV/HCV-related hepatocellular carcinoma tumorigenesis

Current Pharmaceutical Design

Volumn 20, Issue 11, 2014, Pages 1715-1725

  Liang, Rongrui ^a,c   Huang, Na ^a   Li, Zongfang ^a   Ji, Fanpu ^a   Jiang, Shiwen ^b  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

DNA methylation and histone modification; Epigenetic; HBV; HCV; Hepatocellular carcinoma

Indexed keywords

ALPHA INTERFERON; APC PROTEIN; BETA INTERFERON; CADHERIN; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3B; GAMMA INTERFERON; INTERLEUKIN 4 RECEPTOR; METALLOTHIONEIN I; PROTEIN P21; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; STAT1 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; TELOMERASE REVERSE TRANSCRIPTASE; UNTRANSLATED RNA; UVOMORULIN;

ARTICLE; BIOTINYLATION; CANCER GROWTH; CANCER RISK; CELL CYCLE CHECKPOINT; CHROMATIN ASSEMBLY AND DISASSEMBLY; COLON POLYPOSIS; CPG ISLAND; DEACETYLATION; DNA METHYLATION; DNA SEQUENCE; DNA STRAND BREAKAGE; DOWN REGULATION; EPIGENETICS; GENE EXPRESSION; GENOME IMPRINTING; GENOMIC INSTABILITY; HEPATITIS B; HEPATITIS C; HISTONE ACETYLATION; HISTONE MODIFICATION; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SUMOYLATION; TRANSCRIPTION INITIATION SITE; UBIQUITINATION; ANIMAL; COMPLICATION; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; LIVER TUMOR; PATHOLOGY; RISK FACTOR; VIROLOGY;

ANIMALS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATITIS B; HEPATITIS C; HUMANS; LIVER NEOPLASMS; RISK FACTORS;

EID: 84901052574     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990533     Document Type: Article

References (168)

1. Siegel R, Ward E, Brawley O, Jemal A. The impact of eliminating socioeconomic and sacial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-36.
2. Cornella H, Alsinet C, Villanueva A. Molecular pathogenesis of hepatocellular carcinoma. Alcohol Clin Exp Res 2011; 35: 821-5.
3. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-73.
4. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30: 2212-9.
5. Ganem D, Prince AM. Mechanisms of disease: Hepatitis B virus infection-Natural history and clinical consequences. N Engl J Med 2004; 350: 1118-29.
6. Mas VR, Maluf DG, Archer KJ, Yanek K, Bornstein K, Fisher RA. Proteomic analysis of HCV cirrhosis and HCV-induced HCC: Identifying biomarkers for monitoring HCV-cirrhotic patients awaiting liver transplantation. Transplantation 2009; 87: 143-52.
7. Laurent-Puig P, Zucman-Rossi J. Genetics of hepatocellular tumors. Oncogene 2006; 25: 3778-86.
8. Egger G, Liang GN, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429: 457-63.
9. Esteller M. Molecular origins of cancer: Epigenetics in cancer. N Engl J Med 2008; 358: 1148-59.
10. Kim YS, Deng G. Epigenetic changes (aberrant DNA Methylation) in colorectal neoplasia. Gut Liver 2007; 1: 1-11.
11. Jiang Z, Jhunjhunwala S, Liu J, et al. The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients. Genome Res 2012; 22: 593-601.
12. Li Q, Brass AL, Ng A, et al. A genome-wide genetic screen for host factors required for hepatitis C virus propagation. Proc Natl Acad Sci USA 2009; 106: 16410-5.
13. Rosenbaum E, Begum S, Brait M, et al. AIM1 promoter hypermethylation as a predictor of decreased risk of recurrence following radical prostatectomy. Prostate 2012; 72: 1133-9.
14. Sandhu R, Rivenbark AG, Coleman WB. Loss of posttranscriptional regulation of DNMT3b by microRNAs: A possible molecular mechanism for the hypermethylation defect observed in a subset of breast cancer cell lines. Int J Oncol 2012; 41: 721-32.
15. Draht MXG, Riedl RR, Niessen H, et al. Promoter CpG island methylation markers in colorectal cancer: the road ahead. Epigenomics 2012; 4: 179-94.
16. Feng Z, Xie Q, Chen W. Epigenetic and genetic alterations-based molecular classification of head and neck cancer. Expert Rev Mol Diagn 2012; 12: 279-90.
17. Khan SI, Aumsuwan P, Khan IA, Walker LA, Dasmahapatra AK. Epigenetic events associated with breast cancer and their prevention by dietary components targeting the epigenome. Chem Res Toxicol 2012; 25: 61-73.
18. Agrawal A, Murphy RF, Agrawal DK. DNA methylation in breast and colorectal cancers. Mod Pathol 2007; 20: 711-21.
19. Hoque MO. DNA methylation changes in prostate cancer: current developments and future clinical implementation. Expert Rev Mol Diagn 2009; 9: 243-57.
20. Bock C, Walter J, Paulsen M, Lengauer T. CpG island mapping by epigenome prediction. PLoS Comput Biol 2007; 3: 1055-70.
21. Xin Y, O'Donnell AH, Ge Y, et al. Role of CpG context and content in evolutionary signatures of brain DNA methylation. Epigenetics 2011; 6: 1308-18.
22. Aydemir F, Yurtcu E, Balci TB, Sahin FI, Gulsen S, Altinors N. Identification of promoter region methylation patterns of MGMT, CDKN2A, GSTP1, and THBS1 Genes in intracranial meningioma patients. Genet Test Mol Biomarkers 2012; 16: 335-40.
23. Lee H, Zhang P, Herrmann A, et al. Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation. Proc Natl Acad Sci USA 2012; 109: 7765-9.
24. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128: 683-92.
25. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 2002; 21: 5427-40.
26. Ehrlich M. DNA hypomethylation in cancer cells. Epigenomics 2009; 1: 239-59.
27. Ehrlich M, Woods CB, Yu MC, et al. Quantitative analysis of associations between DNA hypermethylation, hypomethylation, and DNMT RNA levels in ovarian tumors. Oncogene 2006; 25: 2636-45.
28. Dunn BK. Hypomethylation: one side of a larger picture. Ann N Y Acad Sci 2003; 983: 28-42.
29. Jiang L, Chan JY-W, Fung K-P. Epigenetic loss of CDH1 correlates with multidrug resistance in human hepatocellular carcinoma cells. Biochem Biophys Res Commun 2012; 422: 739-44.
30. Shen J, Wang S, Zhang Y-J, et al. Genome-wide DNA methylation profiles in hepatocellular carcinoma. Hepatology 2012; 55: 1799-808.
31. Xu L, Li X, Chu ESH, et al. Epigenetic inactivation of BCL6B, a novel functional tumour suppressor for gastric cancer, is associated with poor survival. Gut 2012; 61: 977-85.
32. Fernandez SV, Huang Y, Snider KE, Zhou Y, Pogash TJ, Russo J. Expression and DNA methylation changes in human breast epithelial cells after bisphenol A exposure. Int J Oncol 2012; 41: 369-77.
33. Berman BP, Weisenberger DJ, Aman JF, et al. Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. Nat Genet 2012; 44: 40-6.
34. Hinoue T, Weisenberger DJ, Lange CPE, et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res 2012; 22: 271-82.
35. Balassiano K, Lima S, Jenab M, et al. Aberrant DNA methylation of cancer-associated genes in gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPICEURGAST). Cancer Lett 2011; 311: 85-95.
36. Park J-H, Park J, Choi JK, et al. Identification of DNA methylation changes associated with human gastric cancer. BMC Med Genomics 2011; 4:82.
37. Gao Q, Steine EJ, Barrasa MI, et al. Deletion of the de novo DNA methyltransferase Dnmt3a promotes lung tumor progression. Proc Natl Acad Sci USA 2011; 108: 18061-6.
38. Arai E, Ushijima S, Gotoh M, et al. Genome-wide DNA methylation profiles in liver tissue at the precancerous stage and in hepatocellular carcinoma. Int J Cancer 2009; 125: 2854-62.
39. Stefanska B, Huang J, Bhattacharyya B, et al. Definition of the landscape of promoter DNA hypomethylation in liver cancer. Cancer Res 2011; 71: 5891-903.
40. Hon GC, Hawkins RD, Caballero OL, et al. Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. Genome Res 2012; 22: 246-58.
41. Reinert T, Modin C, Castano FM, et al. Comprehensive genome methylation analysis in bladder cancer: Identification and validation of novel methylated genes and application of these as urinary tumor markers. Clin Cancer Res 2011; 17: 5582-92.
42. Guerrero K, Wang Z, Bachvarova M, et al. A novel genome-based approach correlates TMPRSS3 overexpression in ovarian cancer with DNA hypomethylation. Gynecol Oncol 2012; 125: 720-6.
43. Zeimet AG, Fiegl H, Goebel G, et al. DNA ploidy, nuclear size, proliferation index and DNA-hypomethylation in ovarian cancer. Gynecol Oncol 2011; 121: 24-31.
44. Pohlod-Miller S, Fanning J, Gu P, Crist KA, You M. Detection of genomic alterations in human endometrial cancer by twodimensional gel electrophoresis. Am J Obstet Gynecol 2002; 186: 855-7.
45. Nakagawa T, Kanai Y, Ushijima S, Kitamura T, Kakizoe T, Hirohashi S. DNA hypomethylation on pericentromeric satellite regions significantly correlates with loss of heterozygosity on chromosome 9 in urothelial carcinomas. J Urol 2005; 173: 243-6.
46. Okamoto Y, Sawaki A, Ito S, et al. Aberrant DNA methylation associated with aggressiveness of gastrointestinal stromal tumour. Gut 2012; 61: 392-401.
47. Woo HD, Kim J. Global DNA hypomethylation in peripheral blood leukocytes as a biomarker for cancer risk: a meta-analysis. PloS one 2012; 7: e34615.
48. Ross JP, Rand KN, Molloy PL. Hypomethylation of repeated DNA sequences in cancer. Epigenomics 2010; 2: 245-69.
49. Woloszynska-Read A, Zhang W, Yu J, et al. Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: Association with the BORIS/CTCF expression ratio and advanced stage. Clin Cancer Res 2011; 17: 2170-80.
50. Moore LE, Pfeiffer RM, Poscablo C, et al. Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study. Lancet Oncol 2008; 9: 359-66.
51. Cui HM, Niemitz EL, Ravenel JD, et al. Loss of imprinting of insulin-like growth factor-II in Wilms' tumor commonly involves altered methylation hut not mutations of CTCF or its binding site. Cancer Res 2001; 61: 4947-50.
52. Hubertus J, Lacher M, Rottenkolber M, et al. Altered expression of imprinted genes in Wilms tumors. Oncol Rep 2011; 25: 817-23.
53. Feinberg AP, Tycko B. Timeline-The history of cancer epigenetics. Nat Rev Cancer 2004; 4: 143-53.
54. Murphy SK, Huang ZQ, Wen YQ, et al. Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer. Mol Cancer Res 2006; 4: 283-92.
55. Vu TH, Chuyen NV, Li T, Hoffman AR. Loss of imprinting of IGF2 sense and antisense transcripts in Wilms' tumor. Cancer Res 2003; 63: 1900-5.
56. Fu VX, Schwarze SR, Kenowski ML, LeBlanc S, Svaren J, Jarrard DF. A loss of insulin-like growth factor-2 imprinting is modulated by CCCTC-binding factor down-regulation at senescence in human epithelial cells. J Biol Chem 2004; 279: 52218-26.
57. Pateras IS, Apostolopoulou K, Koutsami M, et al. Downregulation of the KIP family members p27(KIP1) and p57(KIP2) by SKP2 and the role of methylation in p57(KIP2) inactivation in nonsmall cell lung cancer. Int J Cancer 2006; 119: 2546-56.
58. Lai SL, Goepfert H, Gillenwater AM, Luna MA, El-Naggar AK. Loss of imprinting and genetic alterations of the cyclin-dependent kinase inhibitor p57(KIP2) gene in head and neck squamous cell carcinoma. Clin Cancer Res 2000; 6: 3172-6.
59. Maurer S, Fritz J, Muskhelishvili G. A systematic in vitro Study of nucleoprotein complexes formed by bacterial nucleoid-associated proteins revealing novel types of DNA organization. J Mol Biol 2009; 387: 1261-76.
60. Berger SL. The complex language of chromatin regulation during transcription. Nature 2007; 447: 407-12.
61. Ferland CL, Schrader LA. Regulation of histone acetylation in the hippocampus of chronically stressed rats: a potential role of sirtuins. Neuroscience 2011; 174: 104-14.
62. Goldberg AD, Allis CD, Bernstein E. Epigenetics: A landscape takes shape. Cell 2007; 128: 635-8.
63. Cockerill PN. Structure and function of active chromatin and DNase I hypersensitive sites. FEBS J 2011; 278: 2182-210.
64. Morrison AJ, Shen X. Chromatin remodelling beyond transcription: the INO80 and SWR1 complexes. Nature Reviews Molecular Cell Biology 2009; 10: 373-84.
65. Saha A, Wittmeyer J, Cairns BR. Chromatin remodelling: the industrial revolution of DNA around histones. Nat Rev Mol Cell Biol 2006; 7: 437-47.
66. Xu Y, Yan W, Chen X. SNF5, a core component of the SWI/SNF complex, is necessary for p53 expression and cell survival, in part through eIF4E. Oncogene 2010; 29: 4090-100.
67. Lee EJ, Gusev Y, Jiang J, et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 2007; 120: 1046-54.
68. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009; 10: 704-14.
69. Kozaki K-I, Imoto I, Mogi S, Omura K, Inazawa J. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 2008; 68: 2094-105.
70. Schickel R, Boyerinas B, Park SM, Peter ME. MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 2008; 27: 5959-74.
71. Friedman RC, Farh KKH, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19: 92-105.
72. Feng H, Zhang J, Tan JYL, Sadrolodabaee L, Chen WN. Proteomics-related biomarkers for HBV-associated hepatocellular carcinoma: current status and future prospects. Future Virol 2012; 7: 161-71.
73. Hu ZY, Zhang ZS, Kim JW, Huang Y, Liang TJ. Altered proteolysis and global gene expression in hepatitis B virus X transgenic mouse liver. J Virol 2006; 80: 1405-13.
74. Ng RK, Lau CYL, Lee SMY, Tsui SKW, Fung KP, Waye MMY. cDNA microarray analysis of early gene expression profiles associated with hepatitis B virus X protein-mediated hepatocarcinogenesis. Biochem Biophys Res Commun 2004; 322: 827-35.
75. Park IY, Sohn BH, Yu E, et al. Aberrant epigenetic modifications in-hepatocarcinogenesis induced by hepatitis B virus X protein. Gastroenterology 2007; 132: 1476-94.
76. Zheng DL, Zhang L, Cheng N, et al. Epigenetic modification induced by hepatitis B virus X protein via interaction with de novo DNA methyltransferase DNMT3A. J Hepatol 2009; 50: 377-87.
77. Foran E, Garrity-Park MM, Mureau C, et al. Upregulation of DNA methyltransferase-mediated gene silencing, anchorageindependent growth, and migration of colon cancer cells by interleukin-6. Mol Cancer Res 2010; 8: 471-81.
78. Kaur P, Paliwal A, Durantel D, et al. DNA Methylation of hepatitis B virus (HBV) genome associated with the development of hepatocellular carcinoma and occult HBV infection. J Infect Dis 2010; 202: 700-4.
79. Prasad ML, Patel SG, Shah JP, Hoshaw-Woodard S, Busam KJ. Prognostic significance of regulators of cell cycle and apoptosis, p16(INK4a), p53, and bcl-2 in primary mucosal melanomas of the head and neck. Head Neck Pathol 2012; 6: 184-90.
80. Bazarov AV, Lee WJ, Bazarov I, et al. The specific role of pRb in p16(INK4A)-mediated arrest of normal and malignant human breast cells. Cell Cycle 2012; 11: 1008-13.
81. Hu HZ, Li ZG, Chen J, et al. P16 reactivation induces anoikis and exhibits antitumour potency by downregulating Akt/survivin signalling in hepatocellular carcinoma cells. Gut 2011; 60: 710-21.
82. Um TH, Kim H, Oh BK, et al. Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis. J Hepatol 2011; 54: 939-47.
83. Shim YH, Yoon GS, Choi HJ, Chung YH, Yu E. p16 hypermethylation in the early stage of hepatitis B virus-associated hepatocarcinogenesis. Cancer Lett 2003; 190: 213-9.
84. Zhang JC, Yu ZT, Lu J, Li HP, Wu JM, Hu LH. Persistent infection of hepatitis B virus is involved in high rate of p16 methylation in hepatocellular carcinoma. Mol Carcinog 2006; 45: 530-6.
85. Zhu R, Li BZ, Li H, et al. Association of p16(INK4A) hypermethylation with hepatitis B virus X protein expression in the early stage of HBV-associated hepatocarcinogenesis. Pathol Int 2007; 57: 328-36.
86. Zhu YZ, Zhu R, Fan J, et al. Hepatitis B virus X protein induces hypermethylation of p16(INK4A) promoter via DNA methyltransferases in the early stage of HBV-associated hepatocarcinogenesis. J Viral Hepat 2010; 17: 98-107.
87. van der Weyden L, Adams DJ. The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochim Biophys Acta 2007; 1776: 58-85.
88. Li LC, Carroll PR, Dahiya R. Epigenetic changes in prostate cancer: Implication for diagnosis and treatment. J Natl Cancer Inst 2005; 97: 103-15.
89. Trankenschuh W, Puls F, Christgen M, et al. Frequent and distinct aberrations of DNA methylation patterns in fibrolamellar carcinoma of the liver. PloS One 2010; 5:e13688.
90. Saelee P, Wongkham S, Chariyalertsak S, Petmitr S, Chuensumran U. RASSF1A promoter hypermethylation as a prognostic marker for hepatocellular carcinoma. Asian Pac J Cancer Prev 2010; 11: 1677-81.
91. Su H, Zhao J, Xiong YJ, et al. Large-scale analysis of the genetic and epigenetic alterations in hepatocellular carcinoma from Southeast China. Mutat Res 2008; 641: 27-35.
92. Zhang CH, Xu L, Jia WD, et al. Activation of STAT3 signal pathway correlates with twist and E-cadherin expression in hepatocellular carcinoma and their clinical significance. J Surg Res 2012; 174: 120-9.
93. Yang MH, Chen CL, Chau GY, et al. Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma. Hepatology 2009; 50: 1464-74.
94. Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev 2009; 28: 151-66.
95. Hong SM, Omura N, Vincent A, et al. Genome-wide CpG island profiling of intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res 2012; 18: 700-12.
96. Su PF, Lee TC, Lin PJ, et al. Differential DNA methylation associated with hepatitis B virus infection in hepatocellular carcinoma. Int J Cancer 2007; 121: 1257-64.
97. Arzumanyan A, Friedman T, Kotei E, Ng IO, Lian Z, Feitelson MA. Epigenetic repression of E-cadherin expression by hepatitis B virus x antigen in liver cancer. Oncogene 2012; 31: 563-72.
98. Lo HW, Antoun GR, Ali-Osman F. The human glutathione Stransferase P1 protein is phosphorylated and its metabolic function enhanced by the Ser/Thr protein kinases, cAMP-dependent protein kinase and protein kinase C, in glioblastoma cells. Cancer Res 2004; 64: 9131-8.
99. Sakai M, Muramatsu M. Regulation of glutathione transferase P: A tumor marker of hepatocarcinogenesis. Biochem Biophys Res Commun 2007; 357: 575-8.
100. Morsi MI, Hussein AE, Mostafa M, El-Abd E, Abd El-Monem NA. Evaluation of tumour necrosis factor-alpha, soluble P-selectin, gamma-glutamyl transferase, glutathione S-transferase-pi and alpha-fetoprotein in patients with hepatocellular carcinoma before and during chemotherapy. Br J Biomed Sci 2006; 63: 74-78.
101. Niu ZS, Wang M. Expression of c-erbB-2 and glutathione Stransferase-pi in hepatocellular carcinoma and its adjacent tissue. World J Gastroenterol 2005; 11: 4404-8.
102. Nakayama M, Gonzalgo ML, Yegnasubramanian S, Lin XH, De Marzo AM, Nelson WG. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J Cell Biochem 2004; 91: 540-52.
103. Lambert MP, Paliwal A, Vaissiere T, et al. Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake. J Hepatol 2011; 54: 705-15.
104. Park SH, Jung JK, Lim JS, Tiwari I, Jang KL. Hepatitis B virus X protein overcomes all-trans retinoic acid-induced cellular senescence by downregulating levels of p16 and p21 via DNA methylation. J Gen Virol 2011; 92: 1309-17.
105. Zhao J, Wu GB, Bu FF, et al. Epigenetic silence of ankyrin-repeatcontaining, SH3-domain-containing, and proline-rich-regioncontaining protein 1 (ASPP1) and ASPP2 genes promotes tumor growth in hepatitis B virus-positive hepatocellular carcinoma. Hepatology 2010; 51: 142-53.
106. Zheng DL, Zhang L, Cheng N, et al. Epigenetic modification induced by hepatitis B virus X protein via interaction with de novo DNA methyltransferase DNMT3A. J Hepatol 2009; 50: 377-87.
107. Obermajer N, Muthuswamy R, Lesnock J, Edwards RP, Kalinski P. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloidderived suppressor cells. Blood 2011; 118: 5498-505.
108. Yue X, Yang F, Yang Y, et al. Induction of cyclooxygenase-2 expression by hepatitis B virus depends on demethylationassociated recruitment of transcription factors to the promoter. Virol J 2011; 8: 118.
109. Wang SJ, Sakamoto T, Yasuda S, et al. The relationship between telomere length and telomerase activity in gynecologic cancers. Gynecol Oncol 2002; 84: 81-4.
110. Lu L, Zhang C, Zhu G, et al. Telomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome. Breast Cancer Res 2011; 13:R56.
111. Lee JH, Khadka P, Baek SH, Chung IK. CHIP promotes human telomerase reverse transcriptase degradation and negatively regulates telomerase activity. J Biol Chem 2010; 285: 42033-45.
112. Kirkpatrick KL, Ogunkolade W, Elkak AE, et al. hTERT expression in human breast cancer and non-cancerous breast tissue: correlation with tumour stage and c-Myc expression. Breast Cancer Res Treat 2003; 77: 277-84.
113. Oh BK, Kim YJ, Park YN, Choi J, Kim KS, Park C. Quantitative assessment of hTERT mRNA expression in dysplastic nodules of HBV-related hepatocarcinogenesis. Am J Gastroenterol 2006; 101: 831-8.
114. Horikawa I, Barrett JC. cis-Activation of the human telomerase gene (hTERT) by the hepatitis B virus genome. J Natl Cancer Inst 2001; 93: 1171-3.
115. Zhang XD, Dong N, Zhang H, You JC, Wang HH, Ye LH. Effects of hepatitis B virus X protein on human telomerase reverse transcriptase expression and activity in hepatoma cells. J Lab Clin Med 2005; 145: 98-104.
116. Gozuacik D, Murakami Y, Saigo K, et al. Identification of human cancer-related genes by naturally occurring Hepatitis B Virus DNA tagging. Oncogene 2001; 20: 6233-40.
117. Ferber MJ, Montoya DP, Yu C, et al. Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers. Oncogene 2003; 22: 3813-20.
118. Mochizuki T, Sakai K, Iwashita M. Effects of insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) on endometrial cancer (HHUA) cell apoptosis and EGF stimulated cell proliferation in vitro. Growth Horm IGF Res 2006; 16: 202-10.
119. Leibowitz BJ, Cohick WS. Endogenous IGFBP-3 is required for both growth factor-stimulated cell proliferation and cytokineinduced apoptosis in mammary epithelial cells. J Cell Physiol. 2009; 220: 182-8.
120. Lee S, Tarn C, Wang WH, Chen SG, Hullinger RL, Andrisani OM. Hepatitis B virus X protein differentially regulates cell cycle progression in X-transforming versus nontransforming hepatocyte (AML12) cell lines. J Biol Chem 2002; 277: 8730-40.
121. Shona JK, Shon BH, Park IY, et al. Hepatitis B virus-X protein recruits histone deacetylase 1 to repress insulin-like growth factor binding protein 3 transcription. Virus Res 2009; 139: 14-21.
122. Gong Q, Chen S, Guo JJ, et al. Chromosome remodeling related to hepatitis B virus replication in HepG2 cells. DNA Cell Biol 2011; 30: 347-54.
123. Milazzo M, Fornari F, Gramantieri L. MicroRNA and hepatocellular carcinoma: biology and prognostic significance. Minerva Gastroenterol Dietol 2011; 57: 257-71.
124. Liu WH, Yeh SH, Chen PJ. Role of microRNAs in hepatitis B virus replication and pathogenesis. Biochim Biophys Acta 2011; 1809: 678-85.
125. Huang J, Wang Y, Guo Y, Sun S. Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology 2010; 52: 60-70.
126. Yang L, Ma Z, Wang D, Zhao W, Chen L, Wang G. MicroRNA-602 regulating tumor suppressive gene RASSF1A is overexpressed in hepatitis B virus-infected liver and hepatocellular carcinoma. Cancer Biol Ther 2010; 9: 803-8.
127. Zhang X, Liu S, Hu T, Liu S, He Y, Sun S. Up-regulated microRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibronectin expression. Hepatology 2009; 50: 490-9.
128. Yang F, Zhang L, Huo XS, et al. Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor Growth through enhancer of Zeste Homolog 2 in humans. Hepatology 2011; 54: 1679-89.
129. Mosley RT, Edwards TE, Murakami E, et al. Structure of hepatitis C virus polymerase in complex with primer-template RNA. J Virol 2012; 86: 6503-11.
130. Ahmad J, Eng FJ, Branch AD. HCV and HCC: Clinical update and a review of HCC-associated viral mutations in the core gene. Semin Liver Dis 2011; 31: 347-55.
131. Tanaka N, Moriya K, Kiyosawa K, Koike K, Aoyama T. Hepatitis C virus core protein induces spontaneous and persistent activation of peroxisome proliferator-activated receptor alpha in transgenic mice: Implications for HCV-associated hepatocarcinogenesis. Int J Cancer 2008; 122: 124-31.
132. Deng L, Nagano-Fujii M, Tanaka M, et al. NS3 protein of Hepatitis C virus associates with the tumour suppressor p53 and inhibits its function in an NS3 sequence-dependent manner. J Gen Virol 2006; 87: 1703-13.
133. Lan KH, Sheu ML, Hwang SJ, et al. HCVNS5A interacts with p53 and inhibits p53-mediated apoptosis. Oncogene 2002; 21: 4801-11.
134. Kasprzak A, Adamek A. Role of hepatitis C virus proteins (C, NS3, NS5A) in hepatic oncogenesis. Hepatol Res 2008; 38: 1-26.
135. Benegiamo G, Vinciguerra M, Mazzoccoli G, Piepoli A, Andriulli A, Pazienza V. DNA Methyltransferases 1 and 3b Expression in Huh-7 Cells Expressing HCV Core Protein of Different Genotypes. Dig Dis Sci 2012; 57: 1598-603.
136. Nishida N, Nagasaka T, Nishimura T, Ikai I, Boland CR, Goel A. Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology 2008; 47: 908-18.
137. Chim CS, Fung TK, Cheung WC, Liang R, Kwong YL. SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood 2004; 103: 4630-5.
138. Calvisi DF, Ladu S, Gorden A, et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006; 130: 1117-28.
139. Zhang J, Li H, Yu JP, Wang SE, Ren XB. Role of SOCS1 in tumor progression and therapeutic application. Int J Cancer 2012; 130: 1971-80.
140. Uehara E, Takeuchi S, Tasaka T, et al. Aberrant methylation in promoter-associated CpG islands of multiple genes in therapyrelated leukemia. Int J Oncol. 2003; 23: 693-6.
141. Yoshida T, Ogata H, Kamio M, et al. SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis. J Exp Med 2004; 199: 1701-7.
142. Yang B, Guo MZ, Herman JG, Clark DP. Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol 2003; 163: 1101-7.
143. Ko E, Kim SJ, Joh JW, Park CK, Park J, Kim DH. CpG island hypermethylation of SOCS-1 gene is inversely associated with HBV infection in hepatocellular carcinoma. Cancer Lett 2008; 271: 240-50.
144. Qiu WH, David D, Zhou BS, et al. Down-regulation of growth arrest DNA damage-inducible gene 45 beta expression is associated with human hepatocellular carcinoma. Am J Pathol 2003; 162: 1961-74.
145. Ou DL, Shen YC, Yu SL, et al. Induction of DNA damageinducible gene GADD45 beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res 2010; 70: 9309-18.
146. Higashi H, Vallbohmer D, Warnecke-Eberz U, et al. Downregulation of Gadd45 expression is associated with tumor differentiation in non-small cell lung cancer. Anticancer Res 2006; 26: 2143-7.
147. Michaelis KA, Knox AJ, Xu M, et al. Identification of growth arrest and DNA-damage-inducible gene beta (GADD45 beta) as a novel tumor suppressor in pituitary gonadotrope tumors. Endocrinology 2011; 152: 3603-13.
148. Higgs MR, Lerat H, Pawlotsky JM. Downregulation of gadd45 beta expression by hepatitis C virus Leads to defective cell cycle arrest. Cancer Res 2010; 70: 4901-11.
149. Christmann M, Verbeek B, Roos WP, Kaina B. O-6-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: Enzyme activity, promoter methylation and immunohistochemistry. Biochim Biophys Acta 2011; 1816: 179-90.
150. Wirtz S, Nagel G, Eshkind L, Neurath MF, Samson LD, Kaina B. Both base excision repair and O-6-methylguanine-DNA methyltransferase protect against methylation-induced colon carcinogenesis. Carcinogenesis 2010; 31: 2111-7.
151. Brell M, Ibanez J, Tortosa A. O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and metaanalysis of correlation with methylation-specific polymerase chain reaction. BMC Cancer 2011; 11:35.
152. Sansone P, Bromberg J. Targeting the Interleukin-6/Jak/Stat Pathway in Human Malignancies. J Clin Oncol 2012; 30: 1005-14.
153. Yue P, Zhang X, Paladino D, et al. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells. Oncogene 2012; 31: 2309-22.
154. Wang X, Liu Q, Ihsan A, et al. JAK/STAT pathway plays a critical role in the proinflammatory gene expression and apoptosis of RAW264.7 cells induced by trichothecenes as DON and T-2 toxin. Toxicol Sci 2012; 127: 412-24.
155. Horejs-Hoeck J, Schwarz H, Lamprecht S, et al. Dendritic cells activated by IFN-gamma/ STAT1 Express IL-31 receptor and release proinflammatory mediators upon IL-31 treatment. J Immunol 2012; 188: 5319-26.
156. Hofer MJ, Li W, Manders P, et al. Mice deficient in STAT1 but not STAT2 or IRF9 develop a lethal CD4+ T-cell-mediated disease following infection with lymphocytic choriomeningitis virus. J Virol 2012; 86: 6932-46.
157. Duong FHT, Filipowicz M, Tripodi M, La Monica N, Heim MH. Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. Gastroenterology 2004; 126: 263-77.
158. Lee HC, Kim M, Wands JR. Wnt/frizzled signaling in hepatocellular carcinoma. Front Biosci 2006; 11: 1901-15.
159. Lee S, Lee HJ, Kim JH, Lee HS, Jang JJ, Kang GH. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol 2003; 163: 1371-8.
160. Archer KJ, Mas VR, Maluf DG, Fisher RA. High-throughput assessment of CpG site methylation for distinguishing between HCV-cirrhosis and HCV-associated hepatocellular carcinoma. Mol Genet Genomics 2010; 283: 341-9.
161. Duong FHT, Christen V, Lin SS, Heim MH. Hepatitis C virusinduced up-regulation of protein phosphatase 2A inhibits histone modification and DNA damage repair. Hepatology 2010; 51: 741-51.
162. Miura K, Taura K, Kodama Y, Schnabl B, Brenner DA. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology 2008; 48: 1420-9.
163. Verma M, Srivastava S. Epigenetics in cancer: implications for early detection and prevention. Lancet Oncol 2002; 3: 755-63.
164. Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 2004; 4: 707-17.
165. Yu J, Tao Q, Cheung KF, et al. Epigenetic identification of ubiquitin carboxyl-terminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors. Hepatology 2008; 48: 508-18.
166. Chang H, Yi B, Li L, et al. Methylation of tumor associated genes in tissue and plasma samples from liver disease patients. Exp Mol Pathol 2008; 85: 96-100.
167. Liu Y, Mayo MW, Nagji AS, et al. Phosphorylation of RelA/p65 promotes DNMT-1 recruitment to chromatin and represses transcription of the tumor metastasis suppressor gene BRMS1. Oncogene 2012; 31: 1143-54.
168. Zopf S, Ocker M, Neureiter D, et al. Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines. BMC Cancer 2012; 12: 386.